Please enable Javascript
Advanced Renal Cell Carcinoma
Advertisement
CheckMate 9ER Analysis: Potential Role for New Biomarker in Assessing aRCC Treatment
Jordana Jampel
Advanced Renal Cell Carcinoma
|
September 10, 2024
PFS was improved with nivolumab plus cabozantinib.
Read More
Evaluating Front-line Ipilimumab, Nivolumab for Patients With Metastatic RCC
Katy Marshall
Advanced Renal Cell Carcinoma
|
September 6, 2024
A lack of research persists on the duration of therapy as well as the safety and efficacy of reinduction at progression.
Read More
Analyzing Belzutifan Versus Everolimus for Patients With Advanced Renal Cell Carcinoma
Katy Marshall
Advanced Renal Cell Carcinoma
|
August 28, 2024
The hypoxia-inducible factor 2α inhibitor, belzutifan, has shown clinical activity in patients with ccRCC.
Read More
ESMO 2024 Kidney Preview: TiNivo-2, SUNNIFORECAST, CheckMate 9ER, and More
Katy Beckermann, MD, PhD
Advanced Renal Cell Carcinoma
|
September 4, 2024
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
View More
NCCN Guidelines Update: Impact of Ipilimumab and Nivolumab as Preferred Regimen for ccRCC
David Braun, MD, PhD
Advanced Renal Cell Carcinoma
|
August 12, 2024
Dr. Braun shares insights on updates to the NCCN guidelines for RCC, highlighting how they could impact clinical practice.
View More
Comparing Nivolumab, Ipilimumab With Sunitinib for the First-Line Treatment of Advanced RCC
Katy Marshall
Advanced Renal Cell Carcinoma
|
August 5, 2024
Patients who received nivolumab plus ipilimumab experienced increased complete response rates compared with sunitinib.
Read More
Evaluating Real-World Clinical Practice Data of Patients With Metastatic RCC
Katy Marshall
Advanced Renal Cell Carcinoma
|
July 31, 2024
Researchers stated that the novel data source has the potential to inform patient care.
Read More
Talazoparib, Avelumab Show No Clinical Benefit in Patients With Metastatic Kidney Cancer
Katy Marshall
Advanced Renal Cell Carcinoma
|
July 23, 2024
The primary end point was ORR according to Immune Response Evaluation Criteria in Solid Tumors at 4 months.
Read More
Evaluating Bempegaldesleukin, Nivolumab as a First-Line Treatment for Patients With ccRCC
Katy Marshall
Advanced Renal Cell Carcinoma
|
June 27, 2024
Bempegaldesleukin can initialize effector CD8+ T cells and natural killer cells in the tumor microenvironment.
Read More
Advanced, Metastatic Kidney Cancer: Favorable and Very Favorable Risk Stratification
Karine Tawagi, MD
Advancements in Oncology
|
June 12, 2024
Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.
View More
Seq-Cabo: High-Dose Cabozantinib or Nivolumab Combination After Progression in Advanced RCC
Tian Zhang, MD
Advanced Renal Cell Carcinoma
|
July 8, 2024
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
View More
Advancing RCC Treatment: Insights From Dr. Karine Tawagi
GU Oncology Now Editors
Advancements in Oncology
|
June 6, 2024
The discussion focused on advanced and metastatic stages of RCC, shedding light on current practices in clinics.
Read More
Treatment Outcomes for Brain Metastasis From Primary RCC: A National Cancer Database Analysis
Manmeet Ahluwalia, MD, MBA, FASCO
Advanced Renal Cell Carcinoma
|
June 10, 2024
The combination of SRS with IO significantly increases the OS in RCCBM compared with IO, WBRT, or WBRT plus IO.
View More
Key Biomarker Analysis Highlights Effectiveness of Pembrolizumab, Axitinib in Advanced Renal Cell Carcinoma
Brandon Twyford
Advanced Renal Cell Carcinoma
|
June 10, 2024
The KEYNOTE-426 study explored pembrolizumab and axitinib vs sunitinib in advanced RCC using genetic biomarkers.
Read More
Sequential Therapy Outcomes Following Recurrence After Adjuvant Pembrolizumab for RCC
Karl Semaan, MD
Advanced Renal Cell Carcinoma
|
June 5, 2024
Drs. Semaan and El Zarif detail an investigation into first-line systemic therapy following adjuvant immunotherapy for RCC.
View More
Patterns of Progression, Subsequent Therapy in the CLEAR Trial
Viktor Grünwald, MD, PhD
Advanced Renal Cell Carcinoma
|
August 19, 2024
Dr. Grünwald showcases patterns of progression and subsequent therapy for patients receiving len/pembro for aRCC.
View More
Final Analysis of JAVELIN Renal 101 Shows Long-Term Efficacy of Avelumab Plus Axitinib
Emily Menendez
Advanced Renal Cell Carcinoma
|
June 10, 2024
The trial previously demonstrated longer PFS rates with avelumab plus axitinib in patients with PD-L1-positive tumors.
Read More
Updated CLEAR Trial Results: Lenvatinib Plus Pembrolizumab Supported as Standard of Care
Emily Menendez
Advanced Renal Cell Carcinoma
|
June 10, 2024
Patients who received lenvatinib plus pembrolizumab experienced later progression across tumors in multiple organs.
Read More
First-line RCC Systemic Therapy Following Adjuvant Immunotherapy
Zachary Bessette
Advanced Renal Cell Carcinoma
|
June 10, 2024
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
Read More
Efficacy, Safety of Camrelizumab, Apatinib in aRCC After First-line TKI Therapy
Katy Marshall
Advanced Renal Cell Carcinoma
|
June 7, 2024
Investigators found that the median follow-up period was 16.5 months at the study’s cutoff date.
Read More
Load More
Advertisement
Advertisement
Advertisement